Abstract：
:ABO dependent variation in von Willebrand factor (vWf) and procoagulant factor VIII (FVIII) is a plausible mechanism for modulating perioperative hemostasis and bleeding. Group AB has the highest and group O the lowest vWf and FVIII levels. Therefore, we tested the hypothesis that ABO blood group is associated with perioperative transfusion and subsequent survival after coronary revascularization. This retrospective study combined demographic, operative, and transfusion data, including follow-up for a median of 2,096 days, for consecutive aortocoronary bypass (CABG) and CABG/valve procedures from 1996-2009 at a tertiary referral University Heart Center. Between group differences were compared by a Kruskall Wallis test, and hazard ratios [95% confidence intervals] are reported for mortality risk-adjusted Cox proportional hazards regression analysis. From 15,454 patients, follow-up records were available for 13,627 patients: 6,413 group O, 5,248 group A, 1,454 group B, and 435 group AB. Packed red blood cells were the most commonly transfused blood product (3 [0-5] units), while group AB received 2 [0-5] units (Kruskall Wallis Chi squared value for between group differences = 8.2; p = 0.04). Group AB favored improved long-term, postoperative survival (Hazard ratio = 0.82 [95%CI 0.68-0.98]; p = 0.03), which became evident approximately a year after surgery. In conclusion, the procoagulant phenotype of blood group AB is associated with fewer transfusions and improved late survival after cardiac surgery. Whether this finding is related to fewer perioperative transfusions, a reduction in later bleeding or other mechanisms remains speculative.
journal_name
J Thromb Thrombolysisjournal_title
Journal of thrombosis and thrombolysisauthors
Welsby IJ,Phillips-Bute B,Mathew JP,Newman MF,Becker R,Rao S,Milano CA,Stafford-Smith Mdoi
10.1007/s11239-013-1045-2subject
Has Abstractpub_date
2014-10-01 00:00:00pages
402-8issue
3eissn
0929-5305issn
1573-742Xjournal_volume
38pub_type
杂志文章,随机对照试验abstract：:Acutely ill medical patients are at significant risk of venous thromboembolism (VTE). Thromboprophylaxis can substantially reduce the incidence of VTE, but to be optimally effective must consist of the correct choice of agent, at an appropriate dose, and for sufficient duration. Increasing evidence suggests that VTE r...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-011-0594-5
更新日期：2011-10-01 00:00:00
abstract：:Limited evidence exists regarding management of recurrent venous thromboembolism (VTE) that occurs during anticoagulant therapy. We aimed to describe patient characteristics, drug therapy management, and outcomes of patients with VTE recurrence during anticoagulant therapy. We identified 30 relevant episodes of VTE re...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-021-02377-8
更新日期：2021-01-23 00:00:00
abstract：:The recent development and approval of novel oral anticoagulants represents a significant success in the intelligent design of target-specific therapeutics. However, while these agents obviate many of the shortcomings of their predecessor (warfarin), they present novel challenges in pharmacologic management as well. E...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-013-0991-z
更新日期：2014-01-01 00:00:00
abstract：:While antithrombotic therapy of acute myocardial infarction is clearly beneficial, substantial controversy exists regarding the optimal regimen. In particular, while aspirin alone has proven highly effective in reducing rates of reinfarction, stroke, and death following acute coronary occlusion, heparin has not clearl...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/BF01062568
更新日期：1995-01-01 00:00:00
abstract：BACKGROUND:Pharmacoinvasive therapy for the treatment of ST elevation myocardial infarction (STEMI) is a strategy that combines early restoration of coronary flow via pharmacologically induced thrombolysis with subsequent, prompt percutaneous coronary intervention (PCI). Prior studies suggesting a heightened bleeding r...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-005-0344-7
更新日期：2004-12-01 00:00:00
abstract：INTRODUCTION:Recent investigations show that activated factor VII, the primary enzyme in the extrinsic pathway of blood coagulation, exerts additional extra-coagulant functions, such as apoptosis and angiogenesis. On the basis of these recent acquisitions, the present study was aimed to evaluate activated factor VII in...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-006-8969-8
更新日期：2006-10-01 00:00:00
abstract：:Small portable devices that generate a prothrombin time/INR from fingerstick capillary blood simplify warfarin management by allowing selected patients to monitor and manage their own warfarin dose. Early studies established that patients can self-test at home, with results as accurate as those obtained by practitione...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1023/B:THRO.0000014591.32012.1f
更新日期：2003-08-01 00:00:00
abstract：:Differences in genetic makeup or polymorphisms can affect individual drug response. Detecting genetic variation may help predict how a patient will respond to a drug and could be used as a tool to select optimal therapy, tailor dosage regimens, and improve clinical outcomes. The data are replete relative to the therap...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1023/a:1022066305399
更新日期：2002-08-01 00:00:00
abstract：:Since the reports by Weismann and Tobin in 1958 and Roberts et al. in 1964 called attention to paradoxical thrombosis in patients treated with heparin, the thrombotic aspect of the heparin-induced thrombocytopenia syndrome (HIT) has been emphasized. Yet to this day, the mechanism of thrombosis associated with HIT (HIT...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1023/a:1027372901367
更新日期：2000-11-01 00:00:00
abstract：:Tenecteplase, a mutant form of alteplase, possesses pharmacological properties that might favor its use for emergent fibrinolysis of acute pulmonary embolism. Contemporaneous search of the World's literature reveals 14 humans with acute pulmonary embolism treated with tenecteplase. Here, we summarize those cases and r...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-006-9018-3
更新日期：2007-04-01 00:00:00
abstract：:The aim of this study was to evaluate the association of prothrombotic gene polymorphisms [factor V Leiden (FVL) 1691GA, factor VII (FVII) 10976GA, FVII HVR4, platelet membrane glycoproteins GP1BA 1018CT, GP1BA VNTR, integrin ITGB3 1565TC, integrin ITGA2 807CT and methylenetetrahydrofolate reductase (MTHFR) 677C/T], p...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 临床试验,杂志文章
doi：10.1007/s11239-012-0734-6
更新日期：2012-08-01 00:00:00
abstract：:Certain patient populations (pregnancy, cancer, renal impairment, and obesity) may be at higher risk of adverse events during low molecular weight heparin (LMWH) therapy and may benefit from anti-Xa monitoring. Yet, evidence supporting a standardized approach to anti-Xa monitoring correlated to clinical outcomes is la...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-019-01920-y
更新日期：2019-11-01 00:00:00
abstract：BACKGROUND:The missed diagnosis of acute myocardial infarction has been studied in the Emergency Department, but few studies have investigated how often coronary ischemia is correctly identified in the outpatient setting. METHODS:This was a single center retrospective observational study of patients with Health Allian...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-007-0153-2
更新日期：2009-01-01 00:00:00
abstract：BACKGROUND:There are several new strategies proposed to improve the outcome of patients with ST-elevation myocardial infarction (STEMI). One approach is the resurgent use of facilitated percutaneous coronary interventions (PCI). Until recently, deciding whether immediate PCI after combined treatment (facilitated PCI) i...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,随机对照试验
doi：10.1007/s11239-006-5733-z
更新日期：2006-04-01 00:00:00
abstract：:While outpatient anticoagulation services (AMS) have existed extensively for a number of years, inpatient AMS have only recently begun to be implemented on a widespread basis. This is in direct response to anticoagulation regulations set forth by entities such as the Joint Commission (TJC) and the Centers for Medicare...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-011-0563-z
更新日期：2011-04-01 00:00:00
abstract：:Fibrinogen depletion via catalysis by snake venom enzymes as a therapeutic strategy to prevent or treat thrombotic disorders was utilized for over four decades, with ancrod being the quintessential agent. However, ancrod eventually was found to not be of clinical utility in large scale stroke trial, resulting in the e...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-016-1343-6
更新日期：2016-08-01 00:00:00
abstract：:The risk benefit decision in providing anticoagulation for patients with brain metastases is amongst the most difficult decisions faced by clinicians. The purpose of our study was to evaluate both the risk of intracerebral hemorrhage (ICH) associated with anticoagulation therapy and the effect of anticoagulation on su...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,meta分析,评审
doi：10.1007/s11239-017-1536-7
更新日期：2017-10-01 00:00:00
abstract：:Rivaroxaban is a direct factor Xa inhibitor, which is rapidly absorbed in the upper gastrointestinal (GI) tract. In large trials, it has been shown to be effective and safe in VTE treatment. However, in these trials patients with morbid obesity were not reported and it is unknown if the standard dosage of 20 mg rivaro...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-013-0891-2
更新日期：2013-11-01 00:00:00
abstract：:Warfarin is among the ten drugs most commonly involved in adverse drug reactions, has a narrow therapeutic index and complex dosage regimen, exhibits enormous variability dose-response and high risk drug-drug interactions. To analyze the profile of pharmacoepidemiological drug prescriptions for warfarin in patients ad...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 临床试验,杂志文章
doi：10.1007/s11239-013-1030-9
更新日期：2014-05-01 00:00:00
abstract：:To analyze the efficacy and safety of activated prothrombin complex concentrates (aPCC) and four-factor prothrombin complex concentrates (4F-PCC) to prevent hematoma expansion in patients taking apixaban or rivaroxaban with intracranial hemorrhage (ICH). In this multicenter, retrospective study, sixty-seven ICH patien...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-020-02154-z
更新日期：2021-01-01 00:00:00
abstract：:The occurrence of an inhibitor against coagulation factor V (FV) is a rare but challenging condition, which may span from asymptomatic laboratory abnormalities to potentially life-threatening bleeding. The onset of FV inhibitors has been associated most frequently in the past with the patients' exposure to topical bov...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-010-0529-6
更新日期：2011-05-01 00:00:00
abstract：:Stroke and other thromboembolic events are mainly caused by emboli from heart, aorta and other arteries. In this paper we describe a group of 5 middle-aged patients suffering from emboli caused by large thrombi in the aorta. Since the development of giant thrombi under high flow conditions in the aorta is a pathophysi...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-012-0775-x
更新日期：2013-02-01 00:00:00
abstract：:C-reactive protein (CRP) is an independent predictor of risk in ACS patients, and it has been previously shown that percutaneous coronary intervention (PCI) is associated with an early rise in CRP. To assess the long-term relationship between PCI and CRP, we compared CRP levels at baseline, 30 days, 4 months and 24 mo...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,随机对照试验
doi：10.1007/s11239-010-0463-7
更新日期：2010-07-01 00:00:00
abstract：OBJECTIVE:We aimed to determine the relative level of platelet inhibition achieved with low-dose aspirin (81 mg daily) compared with a very low-dose (100 mg every other day). BACKGROUND:The Womens Health Study (WHS) found that a dose of 100 mg every other day of aspirin provided protection against stroke as primary pr...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 临床试验,杂志文章
doi：10.1007/s11239-008-0262-6
更新日期：2009-07-01 00:00:00
abstract：:Sickle cell disease (SCD) is characterised by abnormal coagulopathy and angiogenesis although their relationships in two common genotypes, homozygous (HbSS) SCD and sickle-haemoglobin C disease (HbSC), are unexplored. We measured markers of platelet activation (soluble P-selectin [sP-selectin]), fibrinolysis (D-dimer)...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-007-0177-7
更新日期：2008-04-01 00:00:00
abstract：BACKGROUND:Apoptosis causes myocardiocyte loss during and after myocardial infarction. Therapeutic approaches designed to arrest apoptosis would be a significant new development in the recovery of acute myocardial infarction (AMI). In order to examine apoptotic markers in the circulation, serum levels of p53 and cytoch...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-009-0328-0
更新日期：2010-01-01 00:00:00
abstract：:The use of magnesium therapy for acute myocardial infarction remains controversial despite recent clinical trials such as ISIS-4. Magnesium has numerous beneficial effects in the setting of myocardial infarction, including inhibitory effects on platelet aggregation. Clinical trials of magnesium therapy for myocardial ...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/BF01064375
更新日期：1995-01-01 00:00:00
abstract：:Amniotic fluid embolism (AFE) is a catastrophic condition in the peripartum period and still remains as a leading cause of maternal death. Although over 80% of cases of AFE cases are accompanied by coagulopathy, the pathology of disseminated intravascular coagulation is not well understood not only because of its rari...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-020-02237-x
更新日期：2020-07-29 00:00:00
abstract：:In situ formation of thrombi within the cardiac cavities carries a substantial risk of morbidity and mortality due to the inherent danger of embolization to vital organs. This typically occurs in patients with underlying cardiac disorders associated with low flow state favoring regional stagnation of blood and subsequ...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章,评审
doi：10.1007/s11239-004-0210-z
更新日期：2004-10-01 00:00:00
abstract：:The impact of platelet parameters on the cardiovascular risk is still debated. Gender differences in platelet volume indexes and turnover have been previously reported, potentially conditioning their role in the development of coronary artery disease (CAD). However, few studies have addressed, so far, the impact of ge...
journal_title：Journal of thrombosis and thrombolysis
pub_type： 杂志文章
doi：10.1007/s11239-020-02080-0
更新日期：2020-05-01 00:00:00
